← All tickers

Is REPL Worth Buying in 2026?

Replimune Group, Inc.

STOCK BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Updated 2026-05-03

Here’s whether Replimune Group, Inc. (REPL) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.

🔴
Bearish

Positives: RSI 62 — healthy momentum range. Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-15.40% over 10 days); weak 1-year return of -74.1%; 3-month momentum negative (-64.2%). Currently 81.1% off its 52-week high. Score: -5/7.

Ready to act on this? 📈 Trade on Webull

REPL is trading below its 200-day MA ($6.94) — a key warning sign the longer-term trend is under pressure. An RSI of 62.4 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -74.1% compares to +22.9% for SPY (trailed the market by 96.9%). The current 81.1% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.

$10,000 invested 1 year ago → $2,593 today
vs. S&P 500 (SPY) — same period trailed market by 96.9%

1-Year Price Chart

Daily candles
MA-50 MA-200 Up Down

Signal Check

✗Above 200-day MA ($6.94)
✗Above 50-day MA ($5.89)
✓RSI(14) neutral zone (30–70) — currently 62.4
✗Positive return (-74.1%)
!Within 10% of period high (−81.1%)
Period Range $2.50
$1.50 $13.24
RSI (14) 62.4
0 · OversoldOverbought · 100

Key Metrics

Price$2.50
Period Return-74.1%
Period High$13.24
Period Low$1.50
Drawdown−81.1%
MA-50$5.89
MA-200$6.94
RSI (14)62.4
Avg Volume (30d)8.0M
vs. SPYtrailed by 103.1%
Return Rank#1160 of 1246

Trade REPL

📈 Trade on Webull 📊 Trade on moomoo 💹 Interactive Brokers